The Pharmalot View
Most Read
Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results
Azar has a ‘tin ear’ when it comes to pricing a potential coronavirus treatment
The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?
Kapoor certainly deserves to go to jail, but so do some other pharma execs
If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients
Memo to the Novartis CEO: When in doubt, give the FDA a heads-up
Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain
All Coverage
advertisement
